AzTrials
AzTrials

Acute Respiratory Distress Syndrome (ARDS)SWITCH-ARDSNCT07907276

Early Switch in Moderate ARDS

An observational study of Acute Respiratory Distress Syndrome (ARDS), run by University of Thessaly.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The optimal timing for transition from controlled to assisted mechanical ventilation in patients with acute respiratory distress syndrome (ARDS) remains uncertain. Excessive spontaneous respiratory effort may promote injurious transpulmonary pressure swings and heterogeneous regional ventilation, whereas unnecessary… Read more about this study

Who is it for?
Ages 18 years and older
How many people
30 participants
Where
No sites listed yet
Study dates
1 Oct 2026to 1 Dec 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with ARDS of severe to moderate severity (100<PaO2/FiO2<200 mmHg).

Who may be able to join

  • Age ≥18 years
  • Endotracheally intubated and receiving invasive mechanical ventilation
  • Meets diagnostic criteria for acute respiratory distress syndrome
  • PaO₂/FiO₂ ratio >100 and ≤200 mmHg
  • Receiving controlled mechanical ventilation immediately before the transition trial

Who cannot join

  • Implanted electrical cardiac or other device incompatible with electrical impedance tomography
  • Thoracic drains, extensive dressings, or other factors preventing appropriate EIT belt placement
  • Contraindication to placement of an esophageal balloon catheter
  • Active neuromuscular blockade at initiation of the transition trial
  • Significant hemodynamic instability
  • Any clinical condition for which reduction of sedation or transition to assisted ventilation is considered unsafe by the treating physician

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Apostolos - Alkiviadis Menis, MD, PhD contact

+30 2413501280

menis.ap.alk@proton.me

Demosthenes Makris, MD, PhD contact

+30 2413501280

dimomakris@med.uth.gr

About this study

Official title: Early Switch to Assisted Ventilation in Patients With Moderate ARDS: a Physiological Study

The optimal timing for transition from controlled to assisted mechanical ventilation in patients with acute respiratory distress syndrome (ARDS) remains uncertain. Excessive spontaneous respiratory effort may promote injurious transpulmonary pressure swings and heterogeneous regional ventilation, whereas unnecessary prolongation of controlled ventilation may increase sedation exposure and diaphragmatic dysfunction.

This prospective, single-center physiological interventional study will enroll mechanically ventilated adults with ARDS and a PaO₂/FiO₂ ratio >100 and ≤200 mmHg, measured during PEEP=5 cmH2O, who are receiving controlled mechanical ventilation. Participants will undergo a protocolized 30-minute transition from controlled to assisted mechanical ventilation after reduction of sedation sufficient to allow spontaneous respiratory activity.

Respiratory effort and drive, airway and esophageal pressures, respiratory flow, respiratory mechanics, gas exchange, and regional ventilation measured by electrical impedance tomography will be assessed before and during the transition. Participants will subsequently be followed for 48 hours to determine whether assisted ventilation can be maintained without return to fully controlled mechanical ventilation.

Read the detailed description

Participants meeting eligibility criteria will initially remain on their clinically prescribed controlled mechanical ventilation. Sedation will be gradually reduced to permit the reappearance of spontaneous respiratory activity while avoiding clinically significant agitation or patient-ventilator dyssynchrony. Once spontaneous respiratory activity is present, participants will be transitioned to assisted mechanical ventilation. Positive end-expiratory pressure will be maintained at the pre-transition level, which will have been titrated with the use of esophageal manometry so as to achieve an end-expiratory trans-pulmonary pressure above 0 cmH2O, and inspired oxygen fraction will remain unchanged whenever clinically feasible. Inspiratory assistance will be titrated to maintain protective targets: esophageal pressure swings= 3-15 cmH2O (diaphragm protective) and transpulmonary pressure swings < 15-20 cmH2O (lung protective).

The physiological transition trial will last 30 minutes. Continuous recordings of airway pressure, esophageal pressure, respiratory flow, and electrical impedance tomography will be obtained. Respiratory drive will additionally be assessed using airway occlusion pressure at 100 milliseconds (P0.1).

Three prespecified analysis periods will be used: T0, the final 5 minutes during controlled ventilation before transition; T1, the first 5 minutes of assisted ventilation; and T2, minutes 25-30 of assisted ventilation.

Electrical impedance tomography analyses will include regional distribution of tidal ventilation, global inhomogeneity index, end-expiratory lung impedance, ventral-to-dorsal ventilation distribution, center of ventilation, and occurrence or magnitude of pendelluft. Respiratory mechanics analyses will include esophageal pressure swing, pressure-time product of the esophageal pressure, transpulmonary pressure, respiratory system elastance, chest-wall elastance, and lung elastance.

The transition trial will be stopped if prespecified clinical intolerance or safety criteria occur. Participants who do not tolerate the trial will be returned to controlled ventilation according to clinical requirements.

After completion of the 30-minute trial, participants will be followed for 48 hours. Successful transition will be defined as maintenance of assisted mechanical ventilation without the need to return to fully controlled mechanical ventilation during this period.

Being tested
Protocolized Transition From Controlled to Assisted Mechanical Ventilation
Keywords
pressure support ventilation, acute respiratory distress syndrome, electrical impedance tomography, esophageal pressure, mechanical ventilation, PEEP
Medical subject headings
Respiratory Distress Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Protocolized Transition From Controlled to Assisted Mechanical VentilationOther

    Participants receiving controlled mechanical ventilation will undergo gradual reduction of sedation to permit spontaneous respiratory activity, followed by a 30-minute transition to assisted mechanical ventilation. PEEP will remain at the pre-transition value and FiO₂ will remain unchanged whenever clinically feasible. Inspiratory assistance will be titrated to maintain tidal volume at approximately 6-8 mL/kg predicted body weight. Physiological measurements will be recorded continuously, and the procedure will be terminated if prespecified intolerance or safety criteria occur.

Study groups in NCT07907276
Study groupRoleWhat they receive
Experimental: Protocolized Transition to Assisted Mechanical VentilationNot described
Receives: Other: Protocolized Transition From Controlled to Assisted Mechanical Ventilation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph

    The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. We will measure respiratory rate (breaths per minute).

    Measured: During the first thirty minutes of assisted ventilation.

  2. Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph

    The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. The measured variables will include the lung elastance, the chest wall elastance and the total respiratory system elastance (all measured in cmH₂O/L).

    Measured: During the first thirty minutes of assisted ventilation.

  3. Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph

    The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. The measured variables will include the transpulmonary pressure, which is measured in cmH₂O. During the baseline measurement both statics and dynamics measurements will be calculated, whereas during the assisted phase the investigator will include only the dynamic measurements.

    Measured: During the first thirty minutes of assisted ventilation.

  4. Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph

    The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. We will measure tidal volume (mLs).

    Measured: During the first thirty minutes of assisted ventilation.

Secondary outcomes (6)
  1. Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation

    The investigator will measure the variation in the global inhomogeneity index derived by using electrical impedance tomography.

    Measured: During the first thirty minutes of assisted ventilation.

  2. Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation

    The investigator will measure the end-expiratory lung impedance, EELI, which is measured in ohms.

    Measured: During the first 30-minutes of assisted ventilation.

  3. Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation

    The investigator will measure the ventral to dorsal ratio using the electrical impedance tomography.

    Measured: During the first 30-minutes of assisted ventilation.

  4. Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation

    The investigator will measure the variation in the pendelluft phenomenon using the impedance amplitude values.

    Measured: During the first 30-minutes of assisted ventilation.

  5. Differences in respiratory effort between successful and failed transition to assisted ventilation

    The investigator will measure the differences in esophageal pressure swings, ΔPes in cmH₂O, between the beginning of the transition phase and at the final 5 minutes of the 30-minute trial.

    Measured: During the first 30-minutes of assisted ventilation.

  6. Differences in respiratory effort between successful and failed transition to assisted ventilation.

    The investigator will measure the differences in the esophageal pressure-time product measured in cmH₂O⋅s/min, between the beginning of the transition phase and at the final 5 minutes of the 30-minute trial.

    Measured: During the first 30-minutes of assisted ventilation.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Oct 2026
  2. Study start1 Oct 2026 (estimated)
  3. Primary completion1 Oct 2028 (estimated)
  4. Study completion1 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07907276
Sponsor's protocol ID
SWITCH_MODERATE_ARDS
Acronym
SWITCH-ARDS
Status last verified
Oct 2026
First submitted
8 Sep 2026
Last updated
30 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Respiratory Distress Syndrome (ARDS), run by University of Thessaly.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Apostolos - Alkiviadis Menis, MD, PhD (+30 2413501280, menis.ap.alk@proton.me), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph (time frame: During the first thirty minutes of assisted ventilation.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in